The growing cost-containment pressures in major industrialized nations and continued technological advances will radically change coagulation testing practice during the next ten years. New specific and sensitive markers of hemostasis will be increasingly used on automated instrumentation. Coagulation testing in general, and AT III testing specifically, will become more standardized, offering opportunities for quality control products and services. Moreover, the continuing contraction of the hospital system and technological advances will facilitate decentralization of the AT III testing closer to the patient, creating additional opportunities and challenges for suppliers.This report presents a detailed analysis of the AT III testing market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan, including clinical significance and current laboratory practice, as well as 5-year test volume forecasts by country and market segment.The report examines market applications of chromogenic substrates, monoclonal antibodies, immunoassays, IT, DNA probes, biochips/microarrays, and other technologies; reviews features and operating characteristics of automated analyzers; profiles leading suppliers and recent market entrants developing innovative technologies and products; and identifies alternative... Research Beam Model: Research Beam Product ID: 747277 0 USD New
2016 Antithrombin III Testing Market: Country Forecasts, Innovative Technologies, Competitive Strategies-USA, EU5, Japan
 
 

2016 Antithrombin III Testing Market: Country Forecasts, Innovative Technologies, Competitive Strategies-USA, EU5, Japan

  • Category : Diagnostic and Biotech
  • Published On : September   2016
  • Pages : 197
  • Publisher : VPGMarketResearch.com
 
 
 
The growing cost-containment pressures in major industrialized nations and continued technological advances will radically change coagulation testing practice during the next ten years. New specific and sensitive markers of hemostasis will be increasingly used on automated instrumentation. Coagulation testing in general, and AT III testing specifically, will become more standardized, offering opportunities for quality control products and services. Moreover, the continuing contraction of the hospital system and technological advances will facilitate decentralization of the AT III testing closer to the patient, creating additional opportunities and challenges for suppliers.

This report presents a detailed analysis of the AT III testing market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan, including clinical significance and current laboratory practice, as well as 5-year test volume forecasts by country and market segment.

The report examines market applications of chromogenic substrates, monoclonal antibodies, immunoassays, IT, DNA probes, biochips/microarrays, and other technologies; reviews features and operating characteristics of automated analyzers; profiles leading suppliers and recent market entrants developing innovative technologies and products; and identifies alternative market penetration strategies and entry barriers/risks.

Contains 197 pages and 8 tables
../toc/Antithrombin.pdf
PURCHASE OPTIONS
 
 
 

How can we help you?

Contact us at the Consulting WP office nearest to you or submit a business inquiry online.


  Contact
 

Subscribe to Our Newsletter

 
 
REQUEST SAMPLE    ASK FOR DISCOUNT